Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C
Steady-State Pharmacokinetic Interactions of Green Tea Catechins and Silymarin Flavonolignans in Treatment Naïve Patients With Chronic Hepatitis C Infection
OTHER · University of North Carolinat at Chapel Hill
Study Type
interventional
Actual enrollment (reported)
28
Locations
1 country
Sites
1
Timeline
Study Start
November 2009
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
April 2013
Actual (reported)
Study Completion
July 2013
Actual (reported)
Brief Summary
The purpose of this study is to determine if the safety, metabolism, and antioxidant activity of silymarin and green tea extract are changed when they are given in combination to patients with chronic hepatitis C infection.
Registry Overview
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Recruitment status
completed
Actual enrollment (reported)
28 participants
Study completion date
July 2013
Actual (reported)
Listed locations
1 countries · 1 sites
Trial Relationships
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Related Scientific Literature
Loading related publications...
Study Timeline
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
Study Start
November 2009
Date type not reported
This date has not been verified as actual or estimated.
high dose silymarin and low dose EGCGlow dose silymarin and low dose EGCG
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of silymarin. Females of childbearing potential must be using two reliable forms of effective contraception during the study (while on drug and during follow-up)
Hepatitis C virus (HCV) patients
Any HCV genotype
Never been treated or received less than 50% of standard peg-interferon-based therapy.
No interferon-based therapy in the previous 6 months
Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of screening.
Before entering the study, subjects must agree not to consume alcohol for 48 hours prior to PK sampling days or while on study.
You may not qualify if:
Subjects with any of the following will not be eligible for participation:
Use of other milk thistle or green tea preparations within 30 days of Study Visit 1 (Day 1)
Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, within 30 days of Study Visit 1 (Day 1). A multivitamin at standard doses will be allowed.
Use of diets containing \> 6 servings per day, or 4-6 servings per day from \> 8 of the vegetables and fruits listed in Appendix 2.
Allergy/sensitivity to milk thistle, green tea or their preparations
Inability to tolerate milk products (lactose intolerant)
Use of any interferon-based therapy in the last 6 months.
Use of warfarin, metronidazole or chronic use of acetaminophen greater than two grams per day
Previous liver biopsy that demonstrated presence of cirrhosis or previous liver biopsy that demonstrated greater than or equal to 15% steatosis or evidence of steatohepatitis
Positive test for anti-HIV or HBsAg within 3 years of screening
Positive urine drug screen for drugs of abuse at screening
Alcohol consumption of more than one drink or equivalent (\>12 grams) per day. Patients who consumed more than this in the past must have maintained a level 12 grams or less per day of alcohol consumption for at least six months prior to screening.
History of other chronic liver disease, including metabolic diseases, documented by appropriate test(s)
Women with ongoing pregnancy or breast-feeding, or contemplating pregnancy
FlavonolignansFlavonoidsChromonesBenzopyransPyransHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingPlant PreparationsBiological ProductsComplex MixturesBeveragesDiet, Food, and NutritionPhysiological PhenomenaFood and Beverages
Primary Completion
April 2013
Actual (reported)
Study Completion
July 2013
Actual (reported)
Last Updated
April 18, 2017
Record last verified: 2014-06
Source record
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.